[go: up one dir, main page]

AR022848A1 - Compuestos de imidazol sustituido con un anillo heterociclico de seis o siete miembros que contiene dos atomos de nitrogeno - Google Patents

Compuestos de imidazol sustituido con un anillo heterociclico de seis o siete miembros que contiene dos atomos de nitrogeno

Info

Publication number
AR022848A1
AR022848A1 ARP000100992A ARP000100992A AR022848A1 AR 022848 A1 AR022848 A1 AR 022848A1 AR P000100992 A ARP000100992 A AR P000100992A AR P000100992 A ARP000100992 A AR P000100992A AR 022848 A1 AR022848 A1 AR 022848A1
Authority
AR
Argentina
Prior art keywords
alkyl
substituted
nr8r9
unsubstituted
ring
Prior art date
Application number
ARP000100992A
Other languages
English (en)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AR022848A1 publication Critical patent/AR022848A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Anesthesiology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un compuesto que tiene la formula general ilustrada en la Formula (1) incluyendo los enantiomeros, estereoisomeros, y tautomeros del mismo, así como lassales o solvatos farmacéuticamente aceptables de dichos compuestos (formula 1) donde G es una porcion espaciadora seleccionada entre el grupo que consiste enalquilo C1-7, alqueniloC2-7, alquinilo C2-7, alquilo C1-7-NHCO- y -SO2- donde dicho alquilo, alquenilo o alquinilo está optativamente sustituido con uno o másgrupos seleccionados entre alquilo, arilo, aralquilo, alquilarilo, -O-alquilo y -CO2-alquilo sustituido o no sustituido y donde dichos sustituyentes sonseleccionados entre el grupo que consiste en alquilo, arilo, aralquilo y halogeno y T es un anillo de seis miembros o un anillo desiete miembros que contienedos nitrogenos de anillo y que pertenece a la formula 2 expuesta a continuacion, anillo T que está conectado a dicha porcion G en un átomo de carbono delanillo T o un átomo de nitrogeno de anillo del anillo T donde n es 1 o2 y R2, R3, R4, R5, R6 y R7 pueden ser iguales o diferentes, con la salvedad de queningun par de dichos R3, R4, R5 y R6 puede estar unido al mismo átomo de carbono del anillo T excepto cuando por lo menos uno de dichos R3, R4 R5 y R6 es H,donde dichos R2 y R7 son independientemente seleccionados entre el grupo que consiste en H, alquilo C1-6 sustituido o no sustituido, alquenilo C2-6 sustituidoo no sustituido, alquinilo C2-6 sustituido o no sustituido, arilo, aralquilo, alquilarilo, -C(=O)R8, -CO2R8, SO2R8, S(O)R8, -C(O)NR8R9, - C(=NR8)NR8R9 y dichosR3, R4, R5 y R6 pueden ser iguales o diferentes y son independientemente seleccionados entre el grupo que consiste en H, alquilo C1-6 sustituido o nosustituido, alquenilo C2-6 sustituido o no sustituido, alquinilo C2-6 sustituido o no sustituido, arilo aralquilo, alquilarilo, -C(=O)R8, - CO2R8, - SO2R8,S(O)R8, - C(O)NR8R9, -C(=NR8)NR8R9, -C-O-R8, -OC(O)R8, NR8R9, -SR8, -OH, OR8, -CH2OR8, -CH2N(R8)2, CH2SR8, -NR8(CO)NR8R9, -CX(R8)2, -CX2R8,-CX3, -OCX3, -OCX3,-N(R8)-S(O)R9, -N(R8)-SO2R9, (=O), (=N-OR8), -NR8-SO2-NR8R9, -SO3H y PO3H2, donde R8 y R9 son independientemente H o alquilo C1-6 sustituido o
ARP000100992A 1999-03-08 2000-03-06 Compuestos de imidazol sustituido con un anillo heterociclico de seis o siete miembros que contiene dos atomos de nitrogeno AR022848A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/264,615 US6211182B1 (en) 1999-03-08 1999-03-08 Imidazole compounds substituted with a six or seven membered heterocyclic ring containing two nitrogen atoms

Publications (1)

Publication Number Publication Date
AR022848A1 true AR022848A1 (es) 2002-09-04

Family

ID=23006868

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000100992A AR022848A1 (es) 1999-03-08 2000-03-06 Compuestos de imidazol sustituido con un anillo heterociclico de seis o siete miembros que contiene dos atomos de nitrogeno

Country Status (7)

Country Link
US (1) US6211182B1 (es)
EP (1) EP1159275A2 (es)
JP (1) JP2002539121A (es)
AR (1) AR022848A1 (es)
AU (1) AU3869700A (es)
CA (1) CA2362319A1 (es)
WO (1) WO2000053596A2 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7361666B2 (en) 1999-05-25 2008-04-22 Sepracor, Inc. Heterocyclic analgesic compounds and methods of use thereof
US6635661B2 (en) 2000-05-25 2003-10-21 Sepracor Inc. Heterocyclic analgesic compounds and methods of use thereof
US6677332B1 (en) 1999-05-25 2004-01-13 Sepracor, Inc. Heterocyclic analgesic compounds and methods of use thereof
DE19940130A1 (de) 1999-08-24 2001-03-01 Probiodrug Ges Fuer Arzneim Neue Effektoren der Dipeptidyl Peptidase IV zur topischen Anwendung
WO2001092226A1 (en) * 2000-05-25 2001-12-06 Sepracor, Inc. Heterocyclic analgesic compounds and method of use thereof
ATE411983T1 (de) * 2000-09-20 2008-11-15 Schering Corp Substituierte imidazole als histamine h1 und h3 agonisten oder antagonisten
US20030130199A1 (en) 2001-06-27 2003-07-10 Von Hoersten Stephan Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents
JP2005502623A (ja) * 2001-07-02 2005-01-27 ノボ　ノルディスク　アクティーゼルスカブ 置換ピペラジンおよびジアゼパン
US6844316B2 (en) 2001-09-06 2005-01-18 Probiodrug Ag Inhibitors of dipeptidyl peptidase I
EP1430027B1 (en) * 2001-09-14 2010-09-01 High Point Pharmaceuticals, LLC Novel aminoazetidine, -pyrrolidine and -piperidine derivatives
KR100432577B1 (ko) 2002-02-08 2004-05-24 주식회사유한양행 이미다졸 유도체의 제조방법
KR20110059664A (ko) 2003-05-05 2011-06-02 프로비오드룩 아게 글루타미닐 및 글루타메이트 사이클라제의 이펙터의 용도
WO2004098591A2 (en) * 2003-05-05 2004-11-18 Probiodrug Ag Inhibitors of glutaminyl cyclase and their use in the treatment of neurological diseases
JP2007528860A (ja) * 2003-07-28 2007-10-18 財団法人大阪産業振興機構 血糖降下用組成物
EP2289498A1 (en) 2003-10-15 2011-03-02 Probiodrug AG Use of inhibitors of glutaminyl clyclase
EP1680120A2 (en) * 2003-11-03 2006-07-19 Probiodrug AG Combinations useful for the treatment of neuronal disorders
EP1713780B1 (en) 2004-02-05 2012-01-18 Probiodrug AG Novel inhibitors of glutaminyl cyclase
DE102004061593A1 (de) * 2004-12-21 2006-06-22 Abbott Gmbh & Co. Kg Substituierte N-heterocyclische Verbindungen und ihre therapeutische Verwendung
BRPI0620464A2 (pt) 2005-12-23 2011-11-16 Astrazeneca Ab composto, composição farmacêutica, uso de um composto, e, método para o tratamento de uma doença
US8017612B2 (en) * 2006-04-18 2011-09-13 Japan Tobacco Inc. Piperazine compound and use thereof as a HCV polymerase inhibitor
AU2009303335B2 (en) 2008-10-09 2016-05-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Activators of human pyruvate kinase
AU2010234526B2 (en) 2009-04-06 2016-07-21 Agios Pharmaceuticals, Inc. Pyruvate kinase M2 modulators, therapeutic compositions and related methods of use
WO2010129596A1 (en) 2009-05-04 2010-11-11 Agios Pharmaceuticals, Inc. Pmk2 modulators for use in the treatment of cancer
EP2263672A1 (en) * 2009-05-19 2010-12-22 Bioprojet Novel pharmaceutically acceptable salts of 4-(1H-imidazol-4-ylmethyl)pyridine and their therapeutical uses
JP5856052B2 (ja) 2009-06-29 2016-02-09 アジオス ファーマシューティカルズ， インコーポレイテッド 治療化合物および組成物
EP2448581B1 (en) 2009-06-29 2016-12-07 Agios Pharmaceuticals, Inc. Therapeutic compositions and related methods of use
EP2563761A1 (en) 2010-04-29 2013-03-06 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Activators of human pyruvate kinase
US9221792B2 (en) 2010-12-17 2015-12-29 Agios Pharmaceuticals, Inc N-(4-(azetidine-1-carbonyl) phenyl)-(hetero-) arylsulfonamide derivatives as pyruvate kinase M2 (PMK2) modulators
CA2822432C (en) 2010-12-21 2019-09-24 Agios Pharmaceuticals, Inc. Bicyclic pkm2 activators
TWI549947B (zh) 2010-12-29 2016-09-21 阿吉歐斯製藥公司 治療化合物及組成物
PH12017501176B1 (en) 2011-05-03 2023-03-08 Agios Pharmaceuticals Inc Pyruvate kinase activators for use in therapy
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
HUE063541T2 (hu) 2015-06-11 2024-01-28 Agios Pharmaceuticals Inc Eljárások piruvát-kináz aktivátorok alkalmazására
CA3223869A1 (en) * 2016-09-21 2018-03-29 Vectus Biosystems Limited Compositions for the treatment of hypertension and/or fibrosis

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2586562B1 (fr) 1985-09-02 1989-03-10 Inst Nat Sante Rech Med Composition pharmaceutique contenant de l'a-methylhistamine
GB8916947D0 (en) 1989-07-25 1989-09-13 Smith Kline French Lab Medicaments
GB9115740D0 (en) 1991-07-20 1991-09-04 Smithkline Beecham Plc Medicaments
WO1993012107A1 (en) * 1991-12-18 1993-06-24 Schering Corporation Imidazoylalkyl substituted with a six membered nitrogen containing heterocyclic ring
DE69205287T2 (de) 1991-12-18 1996-03-14 Schering Corp., Kenilworth, N.J. Imidazolylalkyl- piperazin und -diazepin derivate als histamin h3 agonisten/antagonisten.
FR2686084B1 (fr) * 1992-01-10 1995-12-22 Bioprojet Soc Civ Nouveaux derives de l'imidazole, leur preparation et leurs applications therapeutiques.
US5352707A (en) 1992-03-26 1994-10-04 Harbor Branch Oceanographic Institution, Inc. Method for treating airway congestion
HUT74386A (en) 1993-11-15 1996-12-30 Schering Corp Phenyl-alkyl imidazoles as h3-receptor antagonists and pharmaceutical compositions containing them
IL117580A0 (en) * 1995-03-29 1996-07-23 Merck & Co Inc Inhibitors of farnesyl-protein transferase and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
US6211182B1 (en) 2001-04-03
JP2002539121A (ja) 2002-11-19
EP1159275A2 (en) 2001-12-05
WO2000053596A2 (en) 2000-09-14
WO2000053596A3 (en) 2001-01-11
CA2362319A1 (en) 2000-09-14
AU3869700A (en) 2000-09-28

Similar Documents

Publication Publication Date Title
AR022848A1 (es) Compuestos de imidazol sustituido con un anillo heterociclico de seis o siete miembros que contiene dos atomos de nitrogeno
AR033344A1 (es) Compuestos derivados de benzofenonas como inhibidores de la transcriptasa inversa, su uso en la fabricacion de medicamentos, intermediarios y composiciones farmaceuticas
AR040566A1 (es) Derivados de 1-heterociclilalquil 3- sulfonilazaindol o azaindazol como ligandos de 5 hidroxitriptamina-6
AR037907A1 (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
YU48390B (sh) Novi derivati 2-anilinopirimidina, postupak za njihovo dobijanje i sredstva za uništavanje štetočina, koja sadrže ove derivate
DE58905637D1 (de) Verwendung von Adamantan-Derivaten zur Prävention und Behandlung der cerebralen Ischämie.
AR017014A1 (es) Compuestos de triazolo [4,5-d]pirimidina, composiciones farmaceuticas, uso de los mismos para preparar medicamentos y procesos para la preparacionde dichos compuestos
ES2038660T3 (es) Un procedimiento para la preparacion de nuevos benzopiranos con actividad farmacologica.
ES8600305A1 (es) Procedimiento de preparar compuestos beta-lactamicos
LU91196I2 (fr) Picoxystrobin et ses dérivlés pharmaceutiquement acceptables(ACANTO).
CO4700455A1 (es) Derivados tetraciclicos y proceso para su preparacion
ES2192081T3 (es) Derivados de purina antivirales.
SE7601205L (sv) Derivat av omettade aminosyror
AR009413A1 (es) Un compuesto, el cual es un derivado de distamicina benzoheterociclico, su utilizacion, un procedimiento para producirlo y una composicionfarmaceutica que lo comprende
AR043367A2 (es) Derivados de benzofenona, composiciones farmaceuticas y procesos de preparacion.
AR068695A2 (es) Uso de un compuesto de tiazol que comprende un derivado de tiazol para la fabricacion de un medicamento para la prevencion y el tratamiento de en-fermedades causadas por la produccion anormal de citocinas y/o la acele-racion de la adhesion de neutrofilos y/o la produccion anormal de tnf- alfa
ES2103931T3 (es) Imidazoacridinas y su uso antineoplasico.
FI852003L (fi) --laktamantibiotika, foerfarande foer deras framstaellning och deras anvaendning som laekemedel eller tillvaextbefraemjare vid boskapsuppfoedning eller som antioxidanter.
ES8607982A1 (es) Un procedimiento para preparar un derivado de uridina
DE69120603D1 (de) Isochromanderivate
RU95115049A (ru) Производные камптотецина, их получение и противоопухолевая композиция
FI874654A7 (fi) Foerfarande foer framstaellning av terapeutiskt aktiva, nya synergistinderivat.
ES472591A1 (es) Procedimiento para la obtencion de derivados de 1-fenileta- nolamina
ES2077042T3 (es) Derivados de benzoxazina, derivados de benzotiazina y herbicidas que comprenden los mismos.
ES2174582T3 (es) Nuevos derivados de 1,2-ditiolano, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.